VTYX

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

Wall Street analysts forecast VTYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTYX is 13.67 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ventyx Biosciences Inc revenue for the last quarter amounts to -24.87M USD, decreased -35.48 % YoY.

Ventyx Biosciences Inc. EPS for the last quarter amounts to -17558000.00 USD, decreased -50.49 % YoY.

Ventyx Biosciences Inc (VTYX) has 79 emplpoyees as of January 09 2026.

Today VTYX has the market capitalization of 987.60M USD.